NDA[removed]S-021 Page[removed]Rev Sep 2004

First Page		Document Content
Date: 2006-02-08 18:07:21 Chemistry Pharmacology Antiemetics Medicinal plants Cannabinoids Tetrahydrocannabinol Medical cannabis Cannabis Methadone Entheogens Euphoriants Medicine		NDA[removed]S-021 Page[removed]Rev Sep 2004 Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 223,71 KB Share Document on Facebook

	Metabolites account for most of the observed therapeutic effect of the cannabinoids. However, to date, limited research has been conducted in order to identify metabolites and to understand their biological activity and DocID: 1v7wB - View Document
	April 25, 2018 Contaminated Street Drug Supply Synthetic Cannabinoids and Kratom The Ontario Poison Centre (OPC) has been made aware of two separate issues potentially affecting the DocID: 1uHtb - View Document
	Health Advisory: Significant Bleeding Associated with Contaminated Synthetic Cannabinoids DocID: 1uwJY - View Document
	New Test Announcement Expanded Qualitative Synthetic Cannabinoids (K2, SPICE) Test # DocID: 1uriU - View Document
	Synthetic Cannabinoids “Spice” Drugs Confirmations LC-MS/MS and GC-MS using CLEAN SCREEN® THC SPE Column CSTHC206 April 7, PREPARE SAMPLE DocID: 1uqgf - View Document